Serum-derived bovine immunoglobulin for children with diarrhea-predominant irritable bowel syndrome

Background Oral serum-derived bovine immunoglobulin (SBI)/protein isolate is a medical food intended to manage chronic diarrhea. It has been shown to improve pain and diarrhea in adults with diarrhea-predominant irritable bowel syndrome (d-IBS). Aim To determine if SBI can improve symptoms in children with d-IBS. Methods We performed a randomized, double-blind, placebo-controlled, pilot study (NCT02609529) to evaluate the effectiveness of SBI in children 8–18 years with d-IBS. We recorded stool number, abdominal pain, and stool form in all patients for 1 week and then assigned the patients at a ratio of 2:1 to treatment with SBI 5 g BID or placebo for 3 weeks. The patients and their parents completed the Pediatric Quality of Life Inventory™ for Gastrointestinal Symptoms (PedsQOL) and the Pediatric Functional Disability Index (FDI). In addition, complete blood counts and serum chemistries were recorded at the start and end of treatment to evaluate safety. Results Fifteen patients (nine SBI, six placebo) completed the study. Both SBI and placebo groups reported nonstatistical reductions in stool frequency per week. The SBI group showed a significant reduction in stool frequency at weeks 1 and 2 but not at the end of treatment. The SBI group also demonstrated statistical improvements in abdominal pain and stool form by 3 weeks. The placebo group did not achieve similar improvements. The overall FDI and PedsQOL scores, as well as PedsQOL subscale scores for pain, discomfort when eating, diarrhea, worry about stomach aches, and communication, improved significantly in the SBI group, but not in the placebo group. No serious adverse events occurred. Serum chemistries and hemograms were normal at baseline and at the end of study in all patients. Conclusion In this single-center, exploratory pilot study, we demonstrated that 10 g SBI per day was safe in children with d-IBS and improved symptoms. Larger studies, with longer treatment duration, seem warranted based on these initial positive results.

[1]  M. Camilleri,et al.  Potential mechanisms of effects of serum‐derived bovine immunoglobulin/protein isolate therapy in patients with diarrhea‐predominant irritable bowel syndrome , 2017, Physiological reports.

[2]  J. Hinkle,et al.  Absorption and safety of serum-derived bovine immunoglobulin/protein isolate in healthy adults , 2016, Clinical and experimental gastroenterology.

[3]  A. Karpinski,et al.  Functional Gastrointestinal Disorders Dominate Pediatric Gastroenterology Outpatient Practice , 2016, Journal of pediatric gastroenterology and nutrition.

[4]  W. Whitehead,et al.  Episodic Nature of Symptoms in Irritable Bowel Syndrome , 2014, The American Journal of Gastroenterology.

[5]  A. Staiano,et al.  Subtypes of irritable bowel syndrome in children: prevalence at diagnosis and at follow-up. , 2014, The Journal of pediatrics.

[6]  Christopher J. Miller,et al.  Oral serum-derived bovine immunoglobulin improves duodenal immune reconstitution and absorption function in patients with HIV enteropathy , 2013, AIDS.

[7]  M. Evans,et al.  Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects with Diarrhea-Predominant Irritable Bowel Syndrome , 2013, Clinical medicine insights. Gastroenterology.

[8]  M. Camilleri,et al.  Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. , 2012, American journal of physiology. Gastrointestinal and liver physiology.

[9]  J. Varni,et al.  PedsQL Gastrointestinal Symptoms Module Item Development: Qualitative Methods , 2012, Journal of pediatric gastroenterology and nutrition.

[10]  Edgar Erdfelder,et al.  G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences , 2007, Behavior research methods.

[11]  C. Di Lorenzo,et al.  Childhood Functional Gastrointestinal Disorders : Child / Adolescent , 2022 .

[12]  F. Nobili,et al.  Spray-dried plasma improves growth performance and reduces inflammatory status of weaned pigs challenged with enterotoxigenic Escherichia coli K88. , 2004, Journal of animal science.

[13]  W. Whitehead,et al.  Design of Treatment Trials for Functional Gastrointestinal Disorders. , 1999, Gastroenterology.

[14]  A R Zinsmeister,et al.  esign of Treatment Trials for Functional Gastrointestinal isorders esign of Treatment Trials Committee : , 2006 .

[15]  L. Walker,et al.  The functional disability inventory: measuring a neglected dimension of child health status. , 1991, Journal of pediatric psychology.

[16]  D. Czyzewski,et al.  Stooling Characteristics in Children With Irritable Bowel Syndrome , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[17]  B. Stoll,et al.  Dietary plasma protein reduces small intestinal growth and lamina propria cell density in early weaned pigs. , 2000, The Journal of nutrition.